Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-07-07 Sale | 2026-07-09 6:04 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 40,000 | $3.9625 | $158,500 | 6,218,287 (Direct) | View |
| 2026-06-18 Sale | 2026-06-22 4:32 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Bumpus Namandje Director | 3,963 | $3.18 | $12,602 | 127,632 (Direct) | View |
| 2026-06-05 Sale | 2026-06-05 5:03 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.62 | $144,800 | 9,189,072 (Indirect Direct) | View |
| 2026-06-05 Sale | 2026-06-05 5:02 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 23,588 | $3.5806 | $84,459 | 2,175,796 (Direct) | View |
| 2026-06-03 Sale | 2026-06-04 5:04 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Bumpus Namandje Director | 4,386 | $3.54 | $15,526 | 43,171 (Direct) | View |
| 2026-06-02 Sale | 2026-06-04 5:04 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 30,000 | $3.68 | $110,400 | 6,169,863 (Direct) | View |
| 2026-05-22 Sale | 2026-05-27 4:15 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.08 | $123,200 | 9,229,072 (Indirect Direct) | View |
| 2026-05-07 Sale | 2026-05-08 4:59 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.37 | $134,800 | 9,291,893 (Indirect Direct) | View |
| 2026-05-05 Sale | 2026-05-07 4:44 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 30,000 | $3.52 | $105,600 | 6,199,863 (Direct) | View |
| 2026-04-22 Sale | 2026-04-24 4:23 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.61 | $144,400 | 9,351,893 (Indirect Direct) | View |
| 2026-04-07 Sale | 2026-04-08 4:58 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.1 | $124,000 | 9,391,893 (Indirect Direct) | View |
| 2026-04-07 Sale | 2026-04-08 4:58 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 30,000 | $3.1 | $93,000 | 6,229,863 (Direct) | View |
| 2026-03-23 Sale | 2026-03-25 4:36 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.25 | $130,000 | 9,431,893 (Indirect Direct) | View |
| 2026-03-17 Sale | 2026-03-18 5:52 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 7,956 | $3.39 | $26,971 | 1,180,318 (Direct) | View |
| 2026-03-09 Sale | 2026-03-11 5:41 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 28,298 | $3.3451 | $94,660 | 2,262,085 (Direct) | View |
| 2026-03-03 Sale | 2026-03-04 4:38 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 170,000 | $3.46 | $588,200 | 6,259,863 (Direct) | View |
| 2026-02-19 Sale | 2026-02-19 7:30 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $3.46 | $138,400 | 9,491,893 (Indirect Direct) | View |
| 2026-02-18 Sale | 2026-02-19 7:30 pm | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 13,426 | $3.08 | $41,352 | 1,195,349 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-07-01 Option Award | 2026-07-02 5:15 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Dar Zavain Director | 5,109 | $0 | 240,764 (Direct) | View |
| 2026-07-01 Option Award | 2026-07-02 5:15 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Li Dean Y Director | 3,747 | $0 | 3,316,377 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Borgeson Blake Director | 88,424 | $0 | 6,258,287 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | HERSHBERG ROBERT Director | 88,424 | $0 | 162,156 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Michor Franziska Director | 88,424 | $0 | 215,477 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Sun Elaine D Director | 88,424 | $0 | 135,981 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Dar Zavain Director | 88,424 | $0 | 235,655 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Li Dean Y Director | 88,424 | $0 | 3,312,630 (Direct) | View |
| 2026-06-17 Option Award | 2026-06-22 4:32 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Bumpus Namandje Director | 88,424 | $0 | 127,632 (Direct) | View |
| 2026-06-15 Tax Withholding | 2026-06-17 5:07 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 5,396 | $3.15 | 1,101,876 (Direct) | View |
| 2026-06-05 Conversion | 2026-06-05 5:03 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,189,072 (Direct) | View |
| 2026-05-22 Conversion | 2026-05-27 4:15 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,229,072 (Direct) | View |
| 2026-05-15 Tax Withholding | 2026-05-19 5:54 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Hallett David Chief Scientific Officer | 26,657 | $3.04 | 1,070,494 (Direct) | View |
| 2026-05-15 Tax Withholding | 2026-05-19 5:54 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 62,701 | $3.04 | 2,199,384 (Direct) | View |
| 2026-05-15 Tax Withholding | 2026-05-19 5:54 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 25,018 | $3.04 | 1,107,272 (Direct) | View |
| 2026-05-15 Tax Withholding | 2026-05-19 5:54 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 22,821 | $3.04 | 9,269,072 (Direct) | View |
| 2026-05-07 Conversion | 2026-05-08 4:59 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 60,000 | $0 | 9,291,893 (Direct) | View |
| 2026-05-07 Gift | 2026-05-08 4:59 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 20,000 | $0 | 9,291,893 (Direct) | View |
| 2026-04-22 Conversion | 2026-04-24 4:23 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,351,893 (Direct) | View |
| 2026-04-06 Tax Withholding | 2026-04-08 4:58 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 48,028 | $3.11 | 1,132,290 (Direct) | View |
| 2026-04-07 Conversion | 2026-04-08 4:58 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,391,893 (Direct) | View |
| 2026-04-01 Option Award | 2026-04-02 4:56 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Dar Zavain Director | 4,902 | $0 | 147,231 (Direct) | View |
| 2026-04-01 Option Award | 2026-04-02 4:56 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Li Dean Y Director | 3,268 | $0 | 3,224,206 (Direct) | View |
| 2026-03-23 Conversion | 2026-03-25 4:36 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,431,893 (Direct) | View |
| 2026-03-16 Tax Withholding | 2026-03-18 5:52 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 7,075 | $3.42 | 1,180,318 (Direct) | View |
| 2026-03-09 Conversion | 2026-03-11 5:41 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 20,000 | $0 | 9,471,893 (Direct) | View |
| 2026-03-09 Gift | 2026-03-11 5:41 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 20,000 | $0 | 9,471,893 (Direct) | View |
| 2026-02-17 Tax Withholding | 2026-02-19 7:30 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Hallett David Chief Scientific Officer | 11,908 | $3.49 | 1,097,151 (Direct) | View |
| 2026-02-17 Tax Withholding | 2026-02-19 7:30 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 27,265 | $3.49 | 9,491,893 (Direct) | View |
| 2026-02-19 Conversion | 2026-02-19 7:30 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Gibson Christopher Director | 40,000 | $0 | 9,491,893 (Direct) | View |
| 2026-02-17 Tax Withholding | 2026-02-19 7:30 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 11,908 | $3.49 | 1,195,349 (Direct) | View |
| 2026-02-17 Tax Withholding | 2026-02-19 7:30 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 14,280 | $3.49 | 2,290,383 (Direct) | View |
| 2026-02-06 Tax Withholding | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 10,364 | $3.98 | 2,304,663 (Direct) | View |
| 2026-02-06 Option Award | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Khan Najat CEO and President | 1,703,892 | $0 | 2,304,663 (Direct) | View |
| 2026-02-06 Tax Withholding | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 11,400 | $3.98 | 1,220,683 (Direct) | View |
| 2026-02-06 Option Award | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Taylor Ben R Chief Financial Officer | 470,533 | $0 | 1,220,683 (Direct) | View |
| 2026-02-06 Tax Withholding | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Hallett David Chief Scientific Officer | 11,400 | $3.98 | 1,109,059 (Direct) | View |
| 2026-02-06 Option Award | 2026-02-10 6:18 pm | N/A N/A | RECURSION PHARMACEUTICALS INC. | RXRX | Hallett David Chief Scientific Officer | 526,318 | $0 | 1,109,059 (Direct) | View |